These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17603216)

  • 1. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
    Inoue S; Ohtani H; Tsujimoto M; Hori S; Sawada Y
    Drug Metab Pharmacokinet; 2007 Jun; 22(3):162-8. PubMed ID: 17603216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
    Yamada Y; Hamaguchi T; Goto M; Muro K; Matsumura Y; Shimada Y; Shirao K; Nagayama S
    Br J Cancer; 2003 Sep; 89(5):816-20. PubMed ID: 12942110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.
    Lee HW; Seong SJ; Kang WY; Ohk B; Gwon MR; Kim BK; Cho S; Cho K; Sung YK; Yoon YR; Kim JG
    Drug Des Devel Ther; 2019; 13():3127-3136. PubMed ID: 31564829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
    Yamamoto K; Imamura H; Furukawa H; Kishimoto T; Tanaka J; Oshiro R; Tatsuta M; Masutani S; Fukunaga M; Nakayama T; Takemoto H; Kondo M; Kamigaki S; Kawasaki T
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1748-51. PubMed ID: 16315929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
    Liu HY; Ding L; Yu Y; Chu Y; Zhu H
    Yao Xue Xue Bao; 2012 Oct; 47(10):1363-9. PubMed ID: 23289150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
    Tanaka T; Fujita S; Tanaka N; Ooka M; Okajima S; Tanaka N
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):841-5. PubMed ID: 15984528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
    Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
    Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats.
    Kobuchi S; Ito Y; Takamatsu D; Sakaeda T
    Eur J Pharm Sci; 2018 Oct; 123():452-458. PubMed ID: 30077713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling.
    Kim TH; Shin S; Shin JC; Bulitta JB; Weon KY; Yoo SD; Park GY; Jeong SW; Kwon DR; Min BS; Woo MH; Shin BS
    Molecules; 2017 Sep; 22(9):. PubMed ID: 28880240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
    Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
    J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
    Takahashi N; Nitta A; Saitou T; Mori Y; Kunii Y; Kikuchi K
    Gan To Kagaku Ryoho; 1988 Aug; 15(8):2319-23. PubMed ID: 3136701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
    Saif MW; Rosen LS; Saito K; Zergebel C; Ravage-Mass L; Mendelson DS
    Anticancer Res; 2011 Feb; 31(2):625-32. PubMed ID: 21378348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
    Damle B; Ravandi F; Kaul S; Sonnichsen D; Ferreira I; Brooks D; Stewart D; Alberts D; Pazdur R
    Clin Cancer Res; 2001 Mar; 7(3):517-23. PubMed ID: 11297242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on the concentrations of 5-fluorouracil (5-FU), tegafur (ET) and uracil in bile: comparison of UFT or FT].
    Tomita T; Tajima T; Ishibashi M; Tagaya N; Aoki H; Itoh S; Kadowaki A; Kogure H; Tajima Y
    Gan To Kagaku Ryoho; 1989 Dec; 16(12):3755-62. PubMed ID: 2512859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
    Fujiwara H; Terashima M; Irinoda T; Takagane A; Abe K; Nakaya T; Yonezawa H; Oyama K; Takahashi M; Saito K; Takechi T; Fukushima M; Shirasaka T
    Eur J Cancer; 2003 Nov; 39(16):2387-94. PubMed ID: 14556932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.